Peptide Interactions with the Gut Microbiome

Your gut harbors roughly 38 trillion bacteria — a population so large and metabolically active that some researchers call it an organ in its own right. These microbes produce vitamins, train your immune system, ferment dietary fiber into short-chain fatty acids, and communicate with your brain through the vagus nerve.

Peptides — short chains of amino acids — are deeply woven into this microbial ecosystem. Some your body produces specifically to police which bacteria survive. Others, like GLP-1 receptor agonists millions now take for diabetes and weight loss, reshape gut bacterial communities as a side effect. Still others are produced by the microbes themselves, creating feedback loops scientists are only beginning to map.

This article reviews the current evidence on how peptides and the gut microbiome influence each other, from endogenous antimicrobial peptides and GLP-1 agonists like semaglutide to gut-healing peptides like BPC-157 and microbiome-derived peptides with therapeutic potential.

Table of Contents

Antimicrobial Peptides: The Gut's Built-In Bouncers
Defensins and Microbiome Shaping
LL-37 (Cathelicidin): Beyond Killing Bacteria
GLP-1 Agonists and the Microbiome
The Bidirectional Loop: How Microbes Regulate GLP-1
BPC-157: Structural Repair Over Microbial Targeting
Larazotide: Sealing the Barrier from the Inside
KPV: Anti-Inflammatory Tripeptide With Microbiome Effects
Microbiome-Derived Peptides: The AMPSphere and Beyond
Summary Table: Peptides and Their Microbiome Effects
The Bottom Line
References

Antimicrobial Peptides: The Gut's Built-In Bouncers

Your intestinal lining doesn't rely on passive barriers alone. Specialized cells — particularly Paneth cells at the base of intestinal crypts — secrete antimicrobial peptides (AMPs) that directly kill or inhibit bacteria, fungi, and viruses. These include defensins, cathelicidins, C-type lectins like RegIIIγ, and lysozyme.

AMPs don't wipe out all bacteria indiscriminately. Instead, they shape microbiome composition — selectively targeting certain species while leaving others intact. Think of them less as antibiotics and more as gardeners, pruning the microbial community to keep it healthy.

A 2024 review in the Journal of Microbiology described this as a "balancing act," noting that AMPs maintain intestinal homeostasis by controlling microbiome composition while simultaneously protecting against pathogens (Yoo et al., 2024). When AMP production goes wrong — either too little or too much — the consequences range from inflammatory bowel disease to metabolic dysfunction.

AMPs control gut bacteria through several mechanisms: membrane disruption (most AMPs are cationic and punch holes in bacterial membranes), biofilm breakdown (particularly LL-37), immune cell recruitment, and selective pressure that favors commensal species over pathogens.

For more on how antimicrobial peptides are being studied as alternatives to antibiotics, see our dedicated research overview.

Defensins and Microbiome Shaping

Defensins are small cationic peptides characterized by a beta-sheet structure stabilized by disulfide bonds. In the gut, the two main families — alpha-defensins and beta-defensins — play distinct roles.

Alpha-Defensins

Paneth cells in the small intestine secrete alpha-defensins (HD5 and HD6 in humans) in response to both gram-positive and gram-negative bacteria, whether alive or dead. This secretion is triggered by bacterial components including lipopolysaccharide, lipoteichoic acid, and muramyl dipeptide.

Here's what's particularly interesting: alpha-defensin deficiencies in mouse models don't change the total number of bacteria in the gut. They change which bacteria dominate. Mice lacking alpha-defensins show reduced Bacteroides abundance and increased Firmicutes, a shift that mirrors the Firmicutes-to-Bacteroidetes ratio commonly associated with obesity and metabolic disease in human studies.

A September 2025 study published in The EMBO Journal from the University of Sydney's Charles Perkins Centre brought this connection into sharp focus. Researchers led by Dr. Stewart Masson found that genetic variants in the mouse defensin locus directly modulated glucose homeostasis by shaping the gut microbiome (Masson et al., 2025). Mice producing higher levels of alpha-defensins had healthier microbiome profiles and were significantly less likely to develop insulin resistance — a primary driver of type 2 diabetes.

The team synthesized these defensin peptides and fed them to mice lacking the relevant genes. The result: protection against the metabolic effects of an unhealthy diet. Professor David James described the defensins as "gardeners of the microbiome."

One caveat: the protective effect was genotype-dependent. Some mouse strains benefited while others fared worse — a finding the researchers said highlights "the importance of personalized medicine."

Beta-Defensins

In the colon, where Paneth cells are absent, epithelial cells produce beta-defensins. Human beta-defensin 1 (hBD-1) is expressed constitutively — it's always on — while hBD-2 and hBD-3 ramp up in response to infection or inflammation. Their antimicrobial targets differ: hBD-1 primarily affects gram-positive commensals, while hBD-2 through hBD-4 are active against E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pyogenes (Xu & Lu, 2020).

Learn more about the full defensin family and its role in host defense.

LL-37 (Cathelicidin): Beyond Killing Bacteria

LL-37 is the only human cathelicidin, produced as an inactive precursor (hCAP18) and then cleaved by proteolytic enzymes to generate the active 37-amino-acid peptide. It works through similar charge-based membrane disruption as defensins, but its roles extend further.

LL-37 recruits immune cells to sites of infection, breaks down bacterial biofilms, and — in a feedback loop with the microbiome — is itself regulated by microbial metabolites. Gut bacteria produce short-chain fatty acids (SCFAs) like butyrate that stimulate LL-37 production in intestinal epithelial cells. This means the composition of your microbiome directly influences how much LL-37 your gut produces, which in turn influences which bacteria survive.

LL-37 and Inflammatory Bowel Disease

Mice lacking the LL-37 homologue (mCRAMP) develop more severe colitis when exposed to dextran sodium sulfate (DSS), a standard chemical model of IBD. The absence of this single peptide leads to greater mucosal destruction, more intense inflammatory infiltration, and worse clinical symptoms (Xu & Lu, 2020).

A 2024 study found that LL-37 significantly improved survival and intestinal epithelial wound healing in experimental necrotizing enterocolitis (NEC), a devastating condition in premature infants where gut barrier failure and microbial invasion cause intestinal tissue death.

LL-37 is currently in clinical trials as both an antimicrobial agent and immunomodulator, though stability and bioavailability remain hurdles.

Not all bacteria sit passively while AMPs patrol. Helicobacter pylori has evolved countermeasures — using host cholesterol to resist LL-37 while selectively blocking hBD-3 production, even as it triggers hBD-2 (Xu & Lu, 2020).

GLP-1 Agonists and the Microbiome

Millions of people now take GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and tirzepatide (Mounjaro, Zepbound) — for type 2 diabetes and obesity. These drugs slow gastric emptying, reduce appetite, and improve insulin sensitivity. But they also reshape the gut microbiome in ways researchers are actively working to understand.

The 2025 Systematic Review

A 2025 systematic review analyzing 38 studies (29 in animals, 9 in humans) examined how GLP-1 agonists alter gut microbial communities (Ibanez et al., 2025). The findings varied by drug:

Semaglutide produced the most striking shifts. In obese mice on a high-fat diet, Akkermansia muciniphila levels increased by roughly 166-fold compared to untreated controls — the largest change of any genus (Wang et al., 2024). Akkermansia is a mucin-degrading bacterium consistently linked to better metabolic health, stronger gut barrier function, and reduced inflammation. Semaglutide also boosted Alistipes, Alloprevotella, and Lactobacillus.

But there's a catch: semaglutide simultaneously reduced overall microbial diversity. Both the ACE index (measuring richness) and Shannon index (measuring evenness) dropped significantly after treatment (Zhang et al., 2024). In microbiome science, diversity loss is generally a red flag associated with inflammation and metabolic dysfunction.

Liraglutide, the most-studied GLP-1 agonist in microbiome research, increased Alistipes, Butyricimonas, Lactobacillus, and Allobaculum — genera associated with short-chain fatty acid production and anti-inflammatory effects.

Dulaglutide treatment increased Bacteroides, Akkermansia, and Ruminococcus, all connected to improved metabolic profiles.

The Diversity Paradox

The semaglutide finding — beneficial species up, overall diversity down — creates a genuine scientific puzzle. Diversity is typically considered a marker of microbiome health. Its reduction during semaglutide treatment likely stems from the drug's appetite-suppressing effects. A clinical trial found that participants on 50 mg oral semaglutide weekly reduced their caloric intake by 39%. Less food means less substrate for microbial fermentation, which can collapse populations of bacteria that depend on specific dietary inputs.

Whether this diversity loss creates long-term problems remains unknown. The metabolic benefits of GLP-1 agonists are well-documented over treatment periods of 1-2 years. But 5- or 10-year microbiome data doesn't exist yet. As one 2026 analysis noted, "the anti-inflammatory and metabolic advantages may be offset" if reduced diversity triggers chronic dysbiosis (Fitzgerald, 2026).

GLP-1 Agonist	Key Bacterial Increases	Key Bacterial Decreases	Diversity Impact
Semaglutide	Akkermansia (166x), Alistipes, Lactobacillus	Romboutsia, Dubosiella, Enterorhabdus	Decreased (ACE, Shannon)
Liraglutide	Alistipes, Butyricimonas, Lactobacillus	Varies by study	Mixed results
Dulaglutide	Bacteroides, Akkermansia, Ruminococcus	Varies by study	Generally maintained

The Bidirectional Loop: How Microbes Regulate GLP-1

The relationship between GLP-1 and the microbiome runs in both directions. While GLP-1 agonists change bacterial populations, gut bacteria actively regulate GLP-1 production.

Here's the mechanism: dietary fiber reaches the colon undigested. Gut bacteria ferment it into short-chain fatty acids — primarily acetate, propionate, and butyrate. These SCFAs bind to free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41) on enteroendocrine L cells, the specialized intestinal cells that produce GLP-1.

This binding triggers GLP-1 secretion. Mice lacking FFAR2 or FFAR3 show impaired GLP-1 release and worse glucose tolerance (Tolhurst et al., 2012).

There's a second pathway too. Gut bacteria convert primary bile acids (produced by the liver) into secondary bile acids through dehydroxylation and hydrolysis. These secondary bile acids bind to the TGR5 receptor on L cells, providing another signal for GLP-1 production (Zeng et al., 2024).

So the loop works like this:

You eat fiber
Gut bacteria ferment it into SCFAs
SCFAs trigger L cells to secrete GLP-1
GLP-1 slows gastric emptying, improves insulin sensitivity, and — via its effects on appetite and digestion — changes the environment gut bacteria live in
These environmental changes shift bacterial populations, which changes SCFA production, which changes GLP-1 secretion

People with type 2 diabetes show altered gut microbiomes and impaired GLP-1 rhythms. Whether the microbiome changes cause the GLP-1 dysfunction or vice versa remains an active area of investigation.

Butyrate also stimulates production of AMPs like LL-37 and beta-defensins through a GPR43-dependent mechanism. The same microbial metabolite that triggers GLP-1 release also reinforces the antimicrobial peptide barrier — overlapping feedback loops between microbial metabolism, hormone secretion, and innate immunity.

BPC-157: Structural Repair Over Microbial Targeting

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It has been studied extensively in animal models for its effects on gut healing — but its relationship with the microbiome is indirect rather than direct.

Unlike defensins or LL-37, BPC-157 doesn't kill bacteria. Its mechanisms center on tissue repair:

Increased blood flow to damaged gut tissue via nitric oxide modulation
Accelerated tissue repair through upregulated growth factor receptor expression
Reduced inflammatory cytokines at sites of injury
Tight junction maintenance that preserves barrier integrity

In rodent studies, BPC-157 has shown protective effects against NSAID-induced gastropathy, alcohol-related ulcers, and experimentally induced colitis (Sikiric et al., 2018). A 2025 presentation at the American College of Gastroenterology described oral BPC-157 as "an emerging adjunct" in gastrointestinal therapy (ACG, 2025).

The microbiome connection is secondary: by repairing the intestinal lining and reducing mucosal inflammation, BPC-157 may create a more hospitable environment for beneficial bacteria. A damaged, inflamed gut favors pathogenic species and disrupts commensal populations. Restoring barrier integrity theoretically allows normal microbiome composition to reestablish itself.

However, no published studies have directly measured microbiome changes following BPC-157 administration. The claims that BPC-157 "restores the microbiome" are mechanistic extrapolations, not demonstrated outcomes.

Important: BPC-157 is not FDA-approved, has no completed human clinical trials for any gastrointestinal indication, and is not legally sold as a supplement. Its evidence base, while extensive in animals, remains preclinical.

For more on gut-healing peptides, see our guides to the best peptides for gut health and peptides for IBS and digestive disorders.

Larazotide: Sealing the Barrier from the Inside

Larazotide acetate (AT-1001) is a synthetic octapeptide that takes a different approach to gut-microbiome interactions. Rather than killing bacteria or healing tissue, it targets the tight junctions between intestinal epithelial cells — the molecular gates that control what passes from the gut lumen into the bloodstream.

Larazotide works by antagonizing zonulin, a protein that opens tight junctions. When zonulin is elevated — as in celiac disease, type 1 diabetes, and various autoimmune conditions — tight junctions widen, allowing bacterial fragments and toxins into circulation. By blocking zonulin receptors, larazotide keeps junctions closed, promoting reassembly of tight junction proteins (ZO-1, occludin, claudins, E-cadherin) while inhibiting myosin light chain kinase (Seiler et al., 2021).

Why This Matters for the Microbiome

Dysbiosis increases intestinal permeability, and increased permeability allows bacterial components to trigger inflammatory cascades that further disrupt microbial balance — a vicious cycle. By restoring barrier integrity, larazotide may interrupt this loop.

A 2020 study in Nature Communications showed that zonulin antagonism with larazotide prevented intestinal barrier breakdown, reduced dysbiosis, and attenuated collagen-induced arthritis in mice — demonstrating that the barrier-microbiome-inflammation axis extends well beyond the gut itself (Tajik et al., 2020).

A 2024 study tested larazotide in an acute pancreatitis rat model, finding that it reduced bacterial translocation — the passage of gut bacteria into sterile organs — by maintaining tight junction integrity (Digestive Diseases and Sciences, 2024).

Larazotide is currently the most clinically advanced peptide targeting intestinal permeability, having completed Phase I and II trials for celiac disease with good tolerability. Phase III trials are ongoing.

KPV: Anti-Inflammatory Tripeptide With Microbiome Effects

KPV (Lys-Pro-Val) is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). At nanomolar concentrations, it inhibits NF-kB and MAP kinase inflammatory signaling — and unlike most peptides discussed here, there's evidence it directly influences microbial communities.

In animal models of colitis, orally delivered KPV reduced body weight loss, colonic myeloperoxidase activity, and histological signs of inflammation. It decreased pro-inflammatory cytokine mRNA levels in both DSS- and TNBS-induced colitis models (Dalmasso et al., 2008).

KPV's mechanism is unusual: it doesn't work through melanocortin receptors, as you might expect from an alpha-MSH derivative. Instead, it's transported into cells by PepT1, a di/tripeptide transporter normally expressed in the small intestine and upregulated in the colon during IBD. This means KPV's uptake actually increases at sites of active inflammation, creating a self-targeting effect.

A study using KPV delivered via a double-network hydrogel found that the peptide not only restored the gut mucosal barrier in inflamed colons but also "markedly augmented the abundance of beneficial microorganisms in gut homeostasis." This represents one of the few direct demonstrations that a therapeutic peptide can reshape the microbiome toward a healthier profile during active disease.

Nanoparticle delivery systems have been developed to improve KPV's targeted delivery, with hyaluronic acid-functionalized nanoparticles achieving therapeutic efficacy at concentrations 12,000-fold lower than free KPV in solution (Xiao et al., 2017).

KPV remains preclinical — no human trials have been completed — but its combination of anti-inflammatory, barrier-protective, and microbiome-modulating effects makes it one of the more promising peptides in this space.

Microbiome-Derived Peptides: The AMPSphere and Beyond

The peptide-microbiome relationship isn't one-directional. Gut bacteria themselves produce antimicrobial peptides — and a 2024 study published in Cell revealed just how vast this microbial pharmacy is.

Led by Santos-Junior and colleagues, the team used machine learning to mine 63,410 metagenomes and 87,920 prokaryotic genomes from diverse habitats worldwide. The result was the AMPSphere: a catalog of 863,498 non-redundant candidate antimicrobial peptides, the vast majority of which had never been described before (Santos-Junior et al., 2024).

To validate their predictions, the researchers synthesized 100 of these peptides and tested them against clinically relevant drug-resistant pathogens. The results were striking: 79 of 100 demonstrated antimicrobial activity, with 63 specifically targeting pathogenic bacteria. These peptides primarily worked by permeabilizing the outer membrane of target bacteria — and all analyzed gut microbiome strains were susceptible to at least four candidate AMPs.

The AMPSphere study suggests that microbiome-derived peptides represent an enormous, largely untapped reservoir for antibiotic discovery. It also reveals that bacteria are engaged in constant chemical warfare with each other — producing peptides that suppress competitors and shape their local microbial environment.

A 2025 study in Nature Microbiology pushed further, using a protein language model (ProteoGPT) to design novel AMPs against multidrug-resistant bacteria from ICU patients. The AI-generated peptides showed potent activity against carbapenem-resistant Acinetobacter with reduced susceptibility to resistance development.

These microbial peptides aren't always beneficial. A 2024 study in eBioMedicine found a gut bacterial peptide mimicking myelin oligodendrocyte glycoprotein (MOG) triggered autoimmune encephalomyelitis in mice — direct evidence that microbial peptides can initiate autoimmune disease through molecular mimicry.

Summary Table: Peptides and Their Microbiome Effects

Peptide	Type	Primary Mechanism	Microbiome Effect	Evidence Level
Alpha-defensins (HD5, HD6)	Endogenous AMP	Membrane disruption	Directly shapes Firmicutes/Bacteroidetes ratio	Animal studies; EMBO 2025
Beta-defensins (hBD-1 to hBD-4)	Endogenous AMP	Membrane disruption	Selective targeting of bacterial groups	In vitro + animal studies
LL-37	Endogenous AMP	Membrane disruption + biofilm breakdown	Regulated by SCFAs; regulates commensal balance	Animal studies; clinical trials
Semaglutide	GLP-1 agonist	Appetite suppression + metabolic effects	Boosts Akkermansia 166x; reduces diversity	Animal + limited human studies
Liraglutide	GLP-1 agonist	Same class as semaglutide	Increases SCFA-producing bacteria	Animal + limited human studies
BPC-157	Synthetic gastric peptide	Tissue repair + angiogenesis	Indirect — improves gut environment	Animal studies only
Larazotide	Synthetic octapeptide	Tight junction regulation	Indirect — reduces bacterial translocation	Phase III clinical trials
KPV	Alpha-MSH tripeptide	NF-kB/MAPK inhibition	Augments beneficial bacteria in colitis models	Animal studies
AMPSphere peptides	Microbiome-derived	Outer membrane permeabilization	Bacteria-to-bacteria competition	In vitro validation; Cell 2024

The Bottom Line

The gut microbiome and peptides exist in a state of constant mutual regulation. Your body produces antimicrobial peptides that shape which bacteria colonize your gut. Those bacteria, in turn, produce metabolites that regulate peptide production and even manufacture their own antimicrobial peptides to outcompete rivals.

For the millions of people taking GLP-1 agonists like semaglutide, the microbiome effects are real and measurable — more Akkermansia, less overall diversity, shifts in SCFA-producing species. Whether these changes represent a benefit, a trade-off, or both depends on factors we don't yet fully understand, including individual genetics, diet, and baseline microbiome composition.

For gut-healing peptides like BPC-157 and barrier-sealing peptides like larazotide, the microbiome effects are mostly indirect — they restore the physical environment that healthy microbial communities need. KPV stands out as a peptide that appears to directly benefit both the mucosal barrier and microbial composition, though it remains early-stage.

The most exciting frontier may be the microbiome itself as a source of new peptide therapeutics. The AMPSphere — 863,498 candidate antimicrobial peptides mined from global microbiome data — represents a pharmaceutical resource we're only beginning to explore.

What's clear is that gut health and peptide biology aren't separate fields. They're a single integrated network, and understanding it is key to everything from managing metabolic disease to developing the next generation of antibiotics.

References

Masson SWC, et al. Genetic variance in the murine defensin locus modulates glucose homeostasis. The EMBO Journal. 2025. DOI: 10.1038/s44318-025-00555-5
Ibanez F, et al. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. PMC12029897
Wang L, et al. Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice. Frontiers in Endocrinology. 2024. PMC11326427
Zhang L, et al. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. European Journal of Pharmacology. 2024. PMID: 38402930
Santos-Junior CD, et al. Discovery of antimicrobial peptides in the global microbiome with machine learning. Cell. 2024;187(14):3761-3778. PMID: 38843834
Tolhurst G, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364-371. PMC3266401
Zeng Y, et al. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio. 2024. PMC10790698
Xu D, Lu W. Defensins: A double-edged sword in host immunity. Frontiers in Immunology. 2020.
Xu & Lu. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World Journal of Gastroenterology. 2021;27(43):7402-7419. PMC8613745
Yoo JY, et al. Balancing act of the intestinal antimicrobial proteins on gut microbiota and health. Journal of Microbiology. 2024. PMC11090926
Seiler CL, et al. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. American Journal of Physiology. 2021. DOI: 10.1152/ajpgi.00386.2020
Tajik N, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nature Communications. 2020;11:1995. DOI: 10.1038/s41467-020-15831-7
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMC2431115
Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640. PMC5498804
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection, and Selye's stress coping response. Gut and Liver. 2020;14(2):153-167. DOI: 10.5009/gnl18490
Fitzgerald K. GLP-1 Agonists, Gut Microbiome Dysbiosis & Inflammation. Dr. Kara Fitzgerald. January 2026. Link
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice. Frontiers in Pharmacology. 2025. Link
Ameliorative effects of larazotide acetate on intestinal permeability and bacterial translocation in acute pancreatitis model in rats. Digestive Diseases and Sciences. 2024. DOI: 10.1007/s10620-024-08326-8
Human microbiome-derived peptide affects the development of experimental autoimmune encephalomyelitis via molecular mimicry. eBioMedicine. 2024. Link
A generative artificial intelligence approach for the discovery of antimicrobial peptides against multidrug-resistant bacteria. Nature Microbiology. 2025. DOI: 10.1038/s41564-025-02114-4